ArticleCancer cell2019
Paradigms for Precision Medicine in Epichaperome Cancer Therapy.
Abstract read
In one paragraph
Article in Cancer cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Post-Translational Modification as an Allosteric Switch in Hsp90: How Dual Phosphorylation Locks Chaperone Complexes into Hyperstabilized States.The journal of physical chemistry letters · 2026Article
- Evolution of Hsp90 targeting: From stress biology to clinical translation.Cell stress & chaperones · 2026Review
- In vivo imaging of heat shock protein 90: Diagnostic tool and support for Hsp90-targeted therapy.Cell stress & chaperones · 2025Review
- Radiosynthesis and Evaluation of [Journal of labelled compounds & radiopharmaceuticals · 2025Article
- Epichaperome-targeted myocardial imaging byClinical and translational imaging · 2024Article
- Hsp90 Promotes Gastric Cancer Cell Metastasis and Stemness by Regulating the Regional Distribution of Glycolysis-Related Metabolic Enzymes in the Cytoplasm.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Synthesis and Characterization of Click Chemical Probes for Single-Cell Resolution Detection of Epichaperomes in Neurodegenerative Disorders.Biomedicines · 2024Article
- Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation.Research square · 2024Article
- Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer.iScience · 2023Article
- Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Cell death & disease · 2023Article
- Structural and functional complexity of HSP90 in cellular homeostasis and disease.Nature reviews. Molecular cell biology · 2023Review
- Unraveling the Mechanism of Epichaperome Modulation by Zelavespib: Biochemical Insights on Target Occupancy and Extended Residence Time at the Site of Action.Biomedicines · 2023Article
- Article
- Capsaicin binds the N-terminus of Hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin).Scientific reports · 2023Article
- Epichaperomics reveals dysfunctional chaperone protein networks.Nature communications · 2023Article
- How aberrant N-glycosylation can alter protein functionality and ligand binding: An atomistic view.Structure (London, England : 1993) · 2023Article
- Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation.Nature communications · 2023Article
- Extracellular protein homeostasis in neurodegenerative diseases.Nature reviews. Neurology · 2023Review
- Integrating Protein Interaction Surface Prediction with a Fragment-Based Drug Design: Automatic Design of New Leads with Fragments on Energy Surfaces.Journal of chemical information and modeling · 2023Article
- Use of Native-PAGE for the Identification of Epichaperomes in Cell Lines.Methods in molecular biology (Clifton, N.J.) · 2023Article
Corrections and comments
- Commented on by
Authors and funding
33 authors.
Nagavarakishore PillarsettyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Komal JhaveriBreast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Tony TaldoneProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Eloisi Caldas-LopesProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Blesida PunzalanDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Suhasini JoshiProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Alexander BolaenderProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Mohammad M UddinProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Anna RodinaProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Pengrong YanProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Anson KuDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Thomas KuDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Smit K ShahProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Serge LyashchenkoRadiochemistry and Molecular Imaging Probes Core, Sloan Kettering Institute, New York, NY 10065, USA.
Eva BurnaziRadiochemistry and Molecular Imaging Probes Core, Sloan Kettering Institute, New York, NY 10065, USA.
Tai WangProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Nicolas LecomteGastrointestinal Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Yelena JanjigianGastrointestinal Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Anas YounesLymphoma Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Connie W BatleviLymphoma Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Monica L GuzmanDivision of Hematology and Medical Oncology, Leukemia Program, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY 10065, USA.
Gail J RobozDivision of Hematology and Medical Oncology, Leukemia Program, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY 10065, USA.
Jacek KoziorowskiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Pat ZanzonicoDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Mary L AlpaughProgram in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
Adriana CorbenDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Shanu ModiBreast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Larry NortonBreast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Steven M LarsonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program in Molecular Pharmacology, Sloan Kettering Institute, New York, NY 10065, USA.
Jason S LewisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program in Molecular Pharmacology, Sloan Kettering Institute, New York, NY 10065, USA.
Gabriela ChiosisBreast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA. Electronic address: chiosisg@mskcc.org.
John F GerecitanoLymphoma Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Mark P S DunphyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: dunphym@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTranslating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DALLA-FAVERA, RICCARDO, ZELENETZ, ANDREW D. · 2016 to 2020
$10.9MLeveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2MProject 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI GEWIRTH, DANIEL T · 2015 to 2019
$6.7MMemorial Sloan Kettering Small Animal Imaging ResearchR24CA083084 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI KOUTCHER, JASON ARTHUR · 1999 to 2006
$4.4MSmall molecule Hsp90 inhibitors in AD treatmentU01AG032969 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2010 to 2014
$3.5MBiomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9MTargeting the heat shock response for the therapy of DLBCLR01CA155226 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIOSIS, GABRIELA, MELNICK, ARI M. · 2011 to 2015
$2.5MA chemical chaperomics platform for ADR56AG061869 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2018 to 2019
$1.8MBiomarkers of response to Hsp90 inhibitors in triple-negative breast cancerR21CA158609 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2012 to 2013
$426kNCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA155226NCI NIH HHS R01 CA172546NCI NIH HHS R21 CA158609NCI NIH HHS R24 CA083084NCI NIH HHS R35 CA232130NIA NIH HHS R56 AG061869NIA NIH HHS U01 AG032969
Abstract
Alterations in protein-protein interaction networks are at the core of malignant transformation but have yet to be translated into appropriate diagnostic tools. We make use of the kinetic selectivity properties of an imaging probe to visualize and measure the epichaperome, a pathologic protein-protein interaction network. We are able to assay and image epichaperome networks in cancer and their engagement by inhibitor in patients' tumors at single-lesion resolution in real time, and demonstrate that quantitative evaluation at the level of individual tumors can be used to optimize dose and schedule selection. We thus provide preclinical and clinical evidence in the use of this theranostic platform for precision medicine targeting of the aberrant properties of protein networks.
Indexed as
AnimalsAntineoplastic AgentsCell Line, TumorDose-Response Relationship, DrugDrug Administration ScheduleEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansMiceMolecular ChaperonesMolecular ImagingNeoplasmsPrecision MedicineProtein Interaction MappingProtein Interaction MapsAntineoplastic AgentsMolecular Chaperonesbiomarkercancer therapyepichaperomehigher-order protein assemblyhyperconnected protein networkskinetic selectivityPET imaging for precision oncologypharmacometricsprecision medicinePU-H71 companion diagnostic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.